Chronic administration of a nitric oxide synthase inhibitor, Nω-nitro-l-arginine, and drug-induced increase in cerebellar cyclic GMP in vivo
- 51 Downloads
Nω-nitro-l-arginine (NG-nitro-l-arginine) is a potent nitric oxide synthase inhibitor which crosses the blood brain barrier and does not undergo extensive metabolism in vivo. In this study, effect of chronic pretreatment of Nω-nitro-l-arginine (75 mg/kg, i.p., twice daily for 7 days) on the harmaline- (100 mg/kg, s.c.), picrotoxin- (4 mg/kg, s.c.), pentylenetetrazole- (50 mg/kg, i.p.), andl-glutamic acid- (400 μg/10 μl/mouse, i.c.v.) induced increase in cerebellar cGMP was assessed. All the four drugs produced significant increase in cerebellar cGMP in vehicle pretreated control animals. Cerebellar cGMP increase induced by harmaline, picrotoxin, andl-glutamic acid was attentuated in Nω-nitro-l-arginine pretreated animals. These results indicate that in vivo cerebellar cGMP levels are increased by the prototype excitatory amino acid receptor agonist,l-glutamic acid and also by the drugs which augment the excitatory amino acid transmission. Furthermore, parenteral chronic administration of Nω-nitro-l-arginine blocks NO synthase in the brain and hence cerebellar cGMP response in chronic Nω-nitro-l-arginine treated animals could be used as a tool to assess the physiological functions of nitric oxide in vivo.
Key WordsNitric oxide Nω-nitro-l-arginine NO synthase cGMP harmaline picrotoxin
Unable to display preview. Download preview PDF.
- 1.Snyder, S. H. 1992. Nitric oxide: First in a new class of neurotransmitters? Science 257:494–496.Google Scholar
- 2.Moncada, S., Palmer, M. J., and Higgs, E. A. 1991. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:109–142.Google Scholar
- 3.Culotta, E. and Koshland, D. E. Jr. 1992. No news is good news. Science 258:1862–1865.Google Scholar
- 4.Garg, U. C., Devi, L., Turndorf, H., Goldfrank, L. R. and Bansinath, M. 1992. Effect of nitric oxide on mitogenesis and proliferation of cerebellar glial cells. Brain Res. 592:208–212.Google Scholar
- 5.Wood, P. L. 1991. Pharmacology of the second messenger, cyclic guanosine 3′, 5′-monophosphate, in the cerebellum. Pharmacol. Rev., 43:1–25.Google Scholar
- 6.Wood, P. L., Emmett, M. R., Rao, T. S., Mick, S. J., Cler, J. A. and Iyenger, S. 1990. In vivo cerebellar cGMP responses: A model system for studies of the NMDA-associated glycine receptor. Pages 223–234,in A. Guidotti, (ed.) Neurotoxicity of Excitatory Amino Acids, Raven Press, New York.Google Scholar
- 7.Bredt, D. S., Hwang, P. M., and Snyder, S. H. 1990. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347:768–770.Google Scholar
- 8.Hecker, M., Mitchell, J. A., Harris, H. J., Katsura, M., Thimermann, C. and Vane, J. R. 1990. Endothelial cells metabolize NG-monomethyl-l-arginine tol-citrulline and subseuqently to L-arginine. Biochem. Biophys. Res. Commun. 167:1037–1043.Google Scholar
- 9.Dwyer, M. A., Bredt, D. S. and Snyder, S. H. 1991. Nitric oxide synthase: irreversible inhibition by L-NG-nitroarginine in brain in vitro and in vivo. Biochem. Biophys. Res. Commun. 176:1136–1141.Google Scholar
- 10.Bansinath, M., Ramabadran, K., Turndorf, H. and Shukla, V. K. 1991. Intracerebroventricular administration of ν-agonists induces convulsions in mice. Brain. Res. Bull. 27:75–79.Google Scholar
- 11.Wood, P. L., Emmett, M. R., Rao, T. S., Cler, J., Mick, S. and Iyenger, S. 1990. Inhibiton of nitric oxide synthase blocks N-methyl-D-aspartate-, quisqualate-, kainate-, harmaline-, and pentylenetetrazole-dependent increases in cerebellar cyclic GMP in vivo. J. Neurochem. 55:346–348.Google Scholar